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Introduction: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a
disease with high symptom burden, of unknown etiology, with no established treatment.
We observed patients with long-standing ME/CFS who got cancer, and who reported
improvement of ME/CFS symptoms after chemotherapy including cyclophosphamide,
forming the basis for this prospective trial.
Materials and methods: This open-label phase II trial included 40 patients with
ME/CFS diagnosed by Canadian criteria. Treatment consisted of six intravenous infusions
of cyclophosphamide, 600–700 mg/m2, given at four-week intervals with follow-up for
18 months, extended to 4 years. Response was defined by self-reported improvements
in symptoms by Fatigue score, supported by Short Form 36 (SF-36) scores, physical
activity measures and other instruments. Repeated measures of outcome variables were
assessed by General linear models. Responses were correlated with specific Human
Leukocyte Antigen (HLA) alleles.
Results: The overall response rate by Fatigue score was 55.0% (22 of 40 patients).
Fatigue score and other outcome variables showed significant improvements compared
to baseline. The SF-36 Physical Function score increased from mean 33.0 at baseline
to 51.5 at 18 months (all patients), and from mean 35.0 to 69.5 among responders.
Mean steps per 24 h increased from mean 3,199 at baseline to 4,347 at 18 months (all
patients), and from 3,622 to 5,589 among responders. At extended follow-up to 4 years
68% (15 of 22 responders) were still in remission. Patients positive for HLA-DQB1∗03:03
and/or HLA-C∗07:04 (n= 12) had significantly higher response rate compared to patients
negative for these alleles (n = 28), 83 vs. 43%, respectively. Nausea and constipation
were common grade 1–2 adverse events. There were one suspected unexpected serious
adverse reaction (aggravated POTS) and 11 serious adverse events in eight patients.
Conclusion: Intravenous cyclophosphamide treatment was feasible for ME/CFS
patients and associated with an acceptable toxicity profile. More than half of the patients
Rekeland et al. Intravenous Cyclophosphamide in ME/CFS
responded and with prolonged follow-up, a considerable proportion of patients reported
ongoing remission. Without a placebo group, clinical response data must be interpreted
with caution. We nevertheless believe a future randomized trial is warranted.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02444091.
Keywords: myalgic encephalomyelitis, chronic fatigue syndrome, ME, CFS, cyclophosphamide, clinical trial,
medical treatment, HLA
INTRODUCTION
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
(ME/CFS) is a disease of unknown etiology characterized
by post-exertional malaise (PEM) (1, 2), sleep disturbances
with inadequate restitution (3), fatigue, pain and sensory
hypersensitivity, cognitive and several other symptoms. The
diagnosis relies on exclusion of other disorders associated with
fatigue, and there are no confirmatory diagnostic tests. Using
the Canadian consensus criteria (4), an estimated 0.1% of the
population suffer from ME/CFS (5), affecting women 3–4 times
more often than men. ME/CFS has profound impact on quality
of life for patients and their caretakers (6, 7). The socio-economic
costs are high, and there is an urgent need for elucidation of the
disease mechanisms, for improved diagnostic approaches, and
for rational treatment (8).
We hypothesized that ME/CFS could be a variant of an
autoimmune disease, with a role for B-cells and possibly
autoantibodies. Several observations suggest that immune
dysregulation and low-grade inflammation may be involved
in the pathogenesis of ME/CFS (9–11). A review (12)
summarizes data indicating autoimmunity as a possible
etiological factor. Mechanisms may include dysregulations
of cytokines (13), alterations in lymphocyte subsets (14) and
presence of autoantibodies (15–17). A study with peptide arrays
demonstrated an immunosignature based on serum antibodies
that separated ME/CFS cases from healthy controls (18). Also,
elderly patients with ME/CFS have an increased risk of B-cell
lymphomas, especially marginal zone lymphomas known to
be associated with autoimmunity or chronic infections (19).
Recent research suggests disturbed turnover of complex lipids,
fatty acids and amino acids and impaired energy metabolism
as possible features of ME/CFS (20–23), possibly linked to
low-grade inflammation (24).
There is evidence for a genetic predisposition in ME/CFS
(25, 26). The immunologically important Human Leukocyte
Antigen (HLA) genes were previously investigated in small
ME/CFS cohorts, and certain class II alleles have been found
more prevalent among patients (27–29). A recent study of a
larger Norwegian cohort of patients and controls, identified
two potential HLA risk alleles, namely HLA-C∗07:04 and HLA-
DQB1∗03:03 (30).
At present, there is no established treatment for ME/CFS. In
our oncology unit, we have observed seven patients with long-
standingME/CFS, who reported significant improvement of their
ME/CFS symptoms after chemotherapy for either malignant
lymphoma or breast cancer. These seven patients all received
chemotherapy including the cytotoxic drugs cyclophosphamide
or ifosfamide, and one patient also received rituximab. We
decided to pursue these observations in separate clinical trials.
Rituximab is a monoclonal antibody that targets CD20 on
the surface of B-cells, resulting in reversible B-cell depletion
(31). Initial small studies testing rituximab in ME/CFS (32–34)
indicated that a subgroup could benefit from B-cell depletion.
However, in a recent Norwegian multicenter, randomized,
double-blind and placebo-controlled trial, we reported no
significant outcome differences between the rituximab and
placebo groups (35).
Cyclophosphamide, an alkylating agent widely used in cancer
treatment (36), induces immunosuppression and is also used
to treat immune-mediated diseases like systemic lupus (SLE),
rheumatoid arthritis, vasculitis, and multiple sclerosis (37–40).
Based on the assumed immune disturbance in ME/CFS, the
observed improvement in ME/CFS symptoms could be due to
the immunosuppressive effect of cyclophosphamide (41).
In 2014, we treated four ME/CFS patients with six infusions of
cyclophosphamide every 4 weeks. Two of the patients reported
substantial improvement of their ME/CFS symptoms, lasting
more than 4 years for one of them. In these pilot experiences,
there were no infections, neutropenia, thrombocytopenia or
unexpected adverse events. We decided to conduct a prospective
trial to further investigate feasibility, efficacy and safety of
cyclophosphamide treatment in ME/CFS patients.
METHODS
Trial Design
The CycloME study (EudraCT no. 2014-004029-41,
ClinicalTrials.gov NCT02444091) was designed as an open-
label phase II trial comprising 40 patients with ME/CFS. The
study was approved by the Regional Committees for Medical
and Health Research Ethics (2014/1672) and by the National
Medicines Agency in Norway. Originally planned for 18 months
follow-up, the protocol was amended for prolonged observation
of patients up to 4 years after start of treatment. The protocol is
available as supporting information (Data Sheet 1).
Setting and Patient Inclusion
Since 2011 patients with a likely diagnosis of ME/CFS have been
referred to the Department of Oncology and Medical Physics,
Haukeland University Hospital (HUH), for possible inclusion in
clinical trials. Based on available information and proximity to
Frontiers in Medicine | www.frontiersin.org 2 April 2020 | Volume 7 | Article 162
Rekeland et al. Intravenous Cyclophosphamide in ME/CFS
the treating hospital, patients previously included in trials with
rituximab and newly referred patients were invited to receive
information about the trial. Following signed informed consent,
the patients were screened for eligibility.
Inclusion criteria were: a diagnosis of ME/CFS according to
the Canadian criteria (4); age 18–66 years; disease duration more
than 2 years; and disease severity mild-to-moderate, moderate,
moderate-to-severe, or severe. Patients with either mild or very
severe disease (completely bedbound and in need of help for all
basic activities of daily living) were not included. The exclusion
criteria and pre-treatment evaluation are detailed in the trial
protocol (Data Sheet 1).
Recruitment lasted from March 2015 until December 2015.
All 40 patients were included at the Department of Oncology
and Medical Physics, HUH. Seven patients had parts of their
treatment and follow-up at the Department of Oncology, Oslo
University Hospital (OUH).
Follow-up was originally completed in August 2017, with
assessments for prolonged follow-up performed in January 2018
and April 2019.
Patient Registrations
At baseline, patients recorded severity of a range of common
ME/CFS symptoms including PEM, fatigue, cognitive symptoms
and pain, using a numerical rating scale of 1–10. During
18 months follow-up, patients were asked to complete a
symptom questionnaire every 2 weeks, recording change or no
change to the same range of symptoms. The relative scale for
symptom change ranged from 0 to 6, in which three denoted
no change from baseline; 4, 5, and 6 slight, moderate, and
major improvement; and 2, 1, and 0 slight, moderate, and
major worsening, respectively. This scale was adapted from
the validated Clinical Global Impression Scale, which has been
used previously in ME/CFS (42). The primary outcome variable
Fatigue score, which has not been validated, was calculated every
second week during follow-up as the mean change score for
the four fatigue-related items: “Fatigue,” “PEM,” “Need for rest,”
and “Daily functioning.” At baseline and every 2 weeks, patients
also recorded their percent function level on a scale from 1 to
100%, where 100% denoted a completely healthy state. A set of
examples was provided to facilitate this assessment. Samples of
all questionnaires are enclosed under Supporting Information
(Data Sheet 1). Outcome measures also included the Short Form
36 Health Survey (SF-36) ver. 1.2 in Norwegian translation
(43, 44), at baseline, every 3 months during follow-up and at
extended follow-up assessments at 24–30 and 38–48 months.
Fatigue Severity Scale was recorded at 3-months intervals until
18 months (45, 46). Physical activity level was recorded using
an electronic SenseWear armband continuously for 5 to 7 days
in a home setting (47, 48), at baseline and repeated in the time
intervals 7–9, 11–12, 17–18, 24–30, and 38–48 months after start
of treatment.
Intervention and Follow-Up
Six 30-minute intravenous infusions of cyclophosphamide
were administered at 4-week intervals with 600 mg/m2 at
the first and 700 mg/m2 at further cycles. Patients received
premedication with ondansetron 8mg and dexamethasone 4mg,
when necessary enforced by aprepitant 125mg day 1, and
80mg days 2 and 3. Patients with hematuria or dysuria in
previous cycles were given oral uromitexan (Data Sheet 1).
Patients used cold-caps (Elasto-Gel R©, Southwest technologies,
North Kansas City, USA) during infusions to reduce hair
thinning. Each infusion was preceded by routine blood tests,
including hematology, and a visit with a physician or study
nurse. After the first and second infusions, a nadir blood
sample was collected between days 10 and 14 after infusion.
If there were no signs of neutropenia or thrombocytopenia
after the first two treatments, no further blood tests between
treatments were required. Throughout the 18 months follow-
up, patients attended consultations with an investigator every
3 months. Adverse events were registered continuously at each
treatment visit and at follow-up every 3 months and summarized
according to Common Toxicity Criteria for Adverse Events
(CTCAE) ver. 4.03. The Viedoc R© electronic CRF system (PCG
Solutions) was used for data collection and management in the
study. There were no interim analyses. The trial was externally
monitored by the Department for Research and Development
at HUH.
Outcomes
Response to treatment was defined as Fatigue score ≥4.5 for a
minimum of 6 consecutive weeks, occurring at any time point
during treatment or within 18 months follow-up. The trial
had two primary endpoints based on this definition: (i) overall
response rate and (ii) changes in Fatigue score compared to
baseline through 18 months follow up. These endpoints were
also analyzed separately for the treatment-naïve patients (with no
previous rituximab exposure).
Secondary endpoints included: (i) response duration
calculated as the sum of response periods each of at least six
consecutive weeks with mean Fatigue score ≥4.5; and changes
from baseline to specific timepoints of (ii) SF-36 scores for
Physical Function subscale (SF-36-PF) and Physical component
summary score (SF-36-PCS); (iii) self-reported percent function
level; (iv) mean number of steps per 24 h. Adverse events during
the 18 months of follow-up from start of treatment were an
additional secondary endpoint.
HLA Typing
High-resolution HLA genotyping was conducted as part of a
larger study (30). In short, HLA-A, -B, -C, -DRB1, -DQB1, -
DQA1, and -DPB1 alleles were genotyped using NGSgo kits and
NGSengine software from GenDX (Utrecht, the Netherlands),
and 2 × 150 bp paired-end sequencing on a Miseq instrument
(Illumina, San Diego, USA) at the Norwegian Sequencing Centre,
Oslo. The association analysis between HLA risk alleles and
clinical response was not specified in the protocol, and was
performed retrospectively in the data analysis phase. Only the
potential HLA risk alleles identified by Lande et al. (30), i.e.,
HLA-C∗07:04 and HLA-DQB1∗03:03, were investigated.
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Statistical Analysis
Descriptive methods were used to characterize the sample, with
mean and standard deviation (SD) for normally distributed data,
and median with range [min-max, or interquartile range (IQR)]
for skewed data. Primary and secondary outcome measures
were analyzed by the intention-to-treat principle. Changes from
baseline through 18 months follow-up were assessed by General
Linear Model for repeated measures (GLM), including time as
a predictor. Greenhouse-Geisser corrections were used for all
GLM analyses because Mauchly’s tests were significant (p <
0.001), indicating violations of the sphericity assumption. The
changes through follow-up, compared to baseline, were assessed
by the within-subjects effects for time. Simple contrasts in the
time domain were used to assess the changes from baseline
to each specific time interval or time point during follow-up,
with the effect sizes from the parameter estimates [means and
95% confidence intervals (CI)]. To assess differences between
groups GLM repeated measures were performed with p-value
(Greenhouse-Geisser corrected) from the interaction time-by-
group. Groups analyzed were sex, ME/CFS severity, ME/CFS
duration, previous rituximab treatment, infection prior to debut
of ME/CFS symptoms, and specific HLA alleles. The distribution
of sex, ME/CFS severity and the proportion of responders
among carriers and non-carriers of the two aforementioned
HLA-alleles, were compared using Odds Ratio (OR) and Fisher’s
exact tests.
All tests were two-sided with a significance level of 0.05.
Missing data were replaced using the last value carried forward
(LVCF) method. All analyses were performed using IBM SPSS
Statistics ver.25 (IBM Corp., Armonk, USA), and Graphpad
Prism ver.8 (GraphPad Software, La Jolla, USA).
Role of the Funding Sources
The research group for ME/CFS at Department of Oncology and
Medical Physics (HUH) has received funding from the Kavli
Trust and the Norwegian Ministry of Health and Care Services.
The HLA sequencing has received funding from the Kavli Trust
and Norwegian Research Council. The funders had no role in
trial design, data collection, analysis, decision to publish, or
preparation of the manuscript.
RESULTS
Study Population
The flow chart for patient screening, inclusion, treatment and
follow-up is shown in Figure 1. Among available referrals
with adequate medical information, we randomly selected 50
patients for eligibility screening. Ten patients were excluded
due to violation of eligibility criteria, or declined to participate.
We included 25 rituximab-naïve patients and 15 patients with
previous rituximab intervention.
Table 1 shows baseline characteristics for all included patients
(n= 40), the rituximab-naïve patients (n= 25), and patients with
(n = 22) or without (n = 18) a response to cyclophosphamide
according to the definition of the primary endpoint of the study.
Medical history and concomitant diseases at
baseline, and concomitant medication during study
follow-up, are summarized in Supplementary Tables 1, 3.
Supplementary Table 2 shows previous treatment by trial
participants. Some kind of cognitive therapy had been tried
by 52.5%, graded exercise or other physical therapy by 45.0%,
adaptive pacing by 37.5%, vitamin B12 injections by 40.0%, and
low dose naltrexone by 37.5%. None of the patients received any
alternative intervention aimed at ME/CFS during the trial.
Thirty-one patients received all preplanned six infusions,
three patients received five infusions, four received four
infusions, and two received three infusions (Figure 1). The
reasons for omitting infusions were either withdrawal of consent
(two cases after cycle 4), or high symptom burden (seven cases).
All the decisions to omit infusions were in agreement with the
trial investigators. Thus, nine patients (22.5%) deviated from the
planned treatment protocol.
Missing Data
For the 18 months study period, there were missing data for the
two patients who withdrew from study after ∼5 months (both
non-responders at the time of withdrawal), and for one non-
responding patient with severe ME/CFS who failed to complete
self-reported forms from 4 months onwards. Except for these
three patients, there were eight missing data items out of 1,560
raw data for the variable Fatigue score. SenseWear activity
armband data were complete at baseline, and had missing data
from the two withdrawals during follow-up.
Primary Outcome
The overall response rate, i.e., proportion of patients with Fatigue
score ≥4.5 for at least six consecutive weeks, was 22 out of 40
patients (55.0%, 95% CI 39.8–69.3%). Among the rituximab-
naïve patients, 14 out of 25 patients achieved a clinical response
(56.0%, 95% CI 36.9–73.4%).
Changes in Fatigue score during 18 months follow-up, with
comparisons of mean Fatigue score at each 3-month interval
to baseline are shown in Figure 2, for all patients (Figure 2A),
rituximab-naïve patients (Figure 2B), patients with a response
(Figure 2C), and no response during follow-up (Figure 2D).
Repeated measures of Fatigue score showed significant increases
from baseline, with similar improvements among the rituximab-
naïve patients as observed in all patients. The Fatigue score
increased significantly from baseline to 9 months after start of
treatment and further through 18 months follow-up. Among
the 18 patients with no response, the Fatigue score decreased
significantly from baseline to 3 and 6 months, and thereafter
returned to near baseline level. Figure 2 also shows the
courses of mean Fatigue score through 18 months’ follow-
up, subgrouped by ME/CFS disease severity (Figure 2E), and
by presence/absence of HLA risk alleles (Figure 2F) in which
patients with HLA-DQB1∗03:03 and/or HLA-C∗07:04 reported
higher improvements of Fatigue score through follow-up than
those negative for these alleles (p= 0.05).
Secondary Outcomes
Changes of SF-36-PF and percent function level through each
3-month interval, and mean steps per 24 h (at baseline, 7–9, 11–
12, and 17–18 months), are shown in Figures 3A–L. Outcomes
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FIGURE 1 | Flow diagram of enrollment, treatment and follow-up in the CycloME study.
are shown for all patients and for the rituximab-naïve group,
as well as for patients with and without response according
to the study criteria. There were significant improvements of
all outcome variables from baseline through 18 months follow-
up among all 40 patients, with mean SF-36-PF increasing from
33.0 at baseline to a maximum 51.5 at 18 months follow-up
(p < 0.001). Among 25 rituximab-naïve patients, mean SF-
36-PF increased from 34.0 at baseline to 49.8 at 18 months
(p = 0.001). Among 22 responders, mean SF-36-PF increased
from 35.0 at baseline to 69.5 at 18 months (p < 0.001). For
18 non-responders there was only a slight increase of SF-36-
PF from 30.6 at baseline to a maximum of 34.4 at 3 months,
and with no significant changes through the remaining study
follow-up. Similar patterns of significant changes were seen
through follow-up, as compared to baseline, for percent function
level and for mean steps per 24 h, and also for SF-36-PCS
(not shown).
Figure 4 shows the courses of SF-36-PF by subgroups.
There were no significant interactions time-by-group for
sex, severity, disease duration, infection prior to ME/CFS,
or previous treatment with rituximab, i.e., the changes in
SF-36-PF over time were similar in all subgroups, except
for HLA risk allele defined subgroups (see below). The
reason for showing SF-36-PF in these plots was to enable
comparison of data to other reported studies, in which SF-
36-PF has often been used. There was no significant overall
interaction between time and ME/CFS severity (p = 0.51),
although the small group (n = 6) with severe disease
had no clinically relevant increase in SF-36-PF, from 8.3
at baseline to a maximum of 11.7 at 12 months follow-
up. The severe ME/CFS group included two patients with
missing data (one withdrawal and one who failed to complete
registration). However, seven patients with moderate-to-severe
disease had similar improvements of the outcome measures
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TABLE 1 | Baseline characteristics of the study population are shown for the intention-to-treat population, for rituximab-naïve patients and for patients with or without
clinical response.
Characteristic All patients (n = 40) Rituximab-naïvea (n = 25) Respondersb (n = 22) Non-respondersc (n = 18)
Female, n (%) 31 (77.5) 18 (72.0) 18 (81.8) 13 (72.2)
Male, n (%) 9 (22.5) 7 (28.0) 4 (18.2) 5 (27.8)
Age, female pts, mean (min–max) 43.0 (25.0–61.1) 41.5 (26.6–54.6) 41.8 (25.0–60.3) 44.6 (26.6–61.1)
Age, male pts, mean (min–max) 37.6 (21.5–53.3) 35.1 (21.5–50.8) 39.5 (21.5–53.3) 36.0 (23.4–50.8)
BMI female ptsd, mean (min–max) 24.5 (17.1–33.1) 24.6 (17.1–33.1) 24.1 (17.1–32.7) 24.9 (19.0–33.1)
BMI male ptsd, mean (min–max) 24.5 (17.4–30.6) 23.4 (17.4–29.2) 25.9 (17.4–30.6) 23.4 (21.1–26.9)
Rituximab-naïvea, n (%) 25 (62.5) 25 (100.0) 14 (63.6) 12 (66.7)
Previous rituximab treatmente, n (%) 15 (37.5) 0 9 (40.9) 6 (33.3)
ME/CFS disease duration
2–5 years, n (%) 7 (17.5) 7 (28.0) 5 (22.7) 2 (11.1)
5–10 years, n (%) 13 (32.5) 7 (28.0) 5 (22.7) 8 (44.4)
10–15 years, n (%) 9 (22.5) 4 (16.0) 6 (27.3) 3 (16.7)
>15 years 11 (27.5) 7 (28.0) 6 (27.3) 5 (27.8)
ME/CFS disease severity
Mild/Moderate, n (%) 14 (35.0) 10 (40.0) 9 (40.9) 5 (27.8)
Moderate, n (%) 13 (32.5) 7 (28.0) 9 (40.9) 4 (22.2)
Moderate/severe, n (%) 7 (17.5) 5 (20.0) 4 (18.2) 3 (16.7)
Severef, n (%) 6 (15.0) 3 (12.0) 0 6 (33.3)
Infection prior to ME/CFSg, n (%) 26 (65.0) 17 (68.0) 15 (68.2) 11 (61.1)
SF36 Physical Functionh, mean (min–max) 33.0 (0–65) 34.0 (0–65) 35.0 (10–65) 30.6 (0–65)
SF36 Physical component summary scorei, mean (min–max) 23.3 (13.5–41.6) 24.5 (14.6–41.6) 23.1 (13.5–41.6) 23.5 (14.6–31.0)
Steps, mean per 24 h, mean (min–max) 3,199 (568–9,637) 3,282 (568–9,637) 3,622 (1,083–8,178) 2,681 (568–9,637)
Total function levelj, mean (min–max) 16.9 (5–40) 17.0 (5–30) 19.3 (10–40) 14.1 (5–25)
HLA-DQB1*03:03 pos, n (%)k 10 (25.0) 6 (24.0) 9 (40.9) 1 (5.6)
HLA-C *07:04 pos, n (%) 4 (10.0) 2 (8.0) 3 (13.6) 1 (5.6)
HLA-DQB1*03:03 and/or HLA-C*07:04 pos, n (%) 12 (30.0) 6 (24.0) 10 (45.5) 2 (11.1)
aPatients with no previous rituximab intervention.
bClinically significant responders, including 18 patients with long response duration (≥30 weeks), three with moderate response duration (14–28 weeks) and one with marginal response
duration (6–12 weeks).
cPatients with no clinically significant response.
dBody Mass Index (kg/m2 ).
ePatients treated with rituximab in previous trial (KTS-2-2010) n = 14, or outside a clinical trial (n = 1).
fTwo of six patients with severe ME/CFS withdrew from the study after four infusions.
gSelf-reported infection prior to onset of ME/CFS disease.
hShort Form 36 (SF-36) physical function subscale (scale 0–100).
iSF-36 Physical Health Summary Score, norm-based with population mean 50.
jBaseline self-reported function level (scale 0–100%).
kHLA-types determined as part of a larger study (30).
as patients with either moderate or mild-to-moderate disease.
Supplementary Figure 1 shows the courses during follow-up, for
the SF-36 subscales Vitality, Social Function, and Bodily Pain
(Supplementary Figures 1A–F), and also the Fatigue Severity
Scale (Supplementary Figures 1G,H), all showing that the
responders report improvement during follow-up which we
interpret to be of clinical significance.
Out of nine patients included in the trial who had received
previous rituximab treatment without reporting improvement
of ME/CFS symptoms, four achieved a clinical response after
cyclophosphamide intervention. Patients with HLA alleles
HLA-DQB1∗03:03 and/or HLA-C∗07:04 reported higher
improvements of SF-36-PF through follow-up than those
negative for these alleles (p= 0.05) (Figure 4F).
Clinical Response Durations
Among the 22 patients with response, the total duration or
response was median 44 weeks (range 6–70 weeks) within 18
months follow-up. Themedian ratio of clinical response duration
to follow-up was 0.56 (range 0.08–0.90). Response duration was
≥ 30 weeks in 18 patients, 14–28 weeks in three patients, and
6–12 weeks in one patient.
The median time to first response was 22 weeks (range 2–
42 weeks). There were no significant differences in time to first
response by sex, disease severity, disease duration, infection
prior to ME/CFS, or by previous rituximab treatment (data
not shown).
Out of 22 responders, 17 patients (77.3%) reported a sustained
response with Fatigue score of least 4.5 at the end of 18 months
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FIGURE 2 | Fatigue score (primary end point), means with 95% CI at time points through 18 months follow-up, from self-reported symptom scores every second
week. The scale is 0–6, where 3 indicates no change from baseline and higher scores indicate less fatigue. (A): All included patients (n = 40). (B): Treatment-naïve
patients (not previously exposed to rituximab, n = 25). (C): Responders during follow-up (n = 22). (D) Non-responders during follow-up (n = 18). P-values from
General Linear Model repeated measures assessing changes in Fatigue score from baseline. (E,F) show mean Fatigue score (with 95% CI) through 18 months’
follow-up, subgrouped by ME/CFS disease severity (E), and presence/absence of HLA risk alleles (F). P-values from General Linear Model for interaction
time-by-group, assessing difference between subgroups in repeated measures of Fatigue score over time compared to baseline. P-values: * <0.05; ** <0.01;
*** <0.001. CI, confidence intervals.
follow-up. Among all 40 included patients, 21 (52.5%) reported
a Fatigue score of at least 4.0 (slight improvement) at end
of follow-up.
Prolonged Follow-Up
Following two approved protocol amendments, patients had
additional visits or telephone interviews with recordings of
SF-36 and percent function level and SenseWear physical
activity measurements at 24–30 and 38–48 months follow-
up. Due to the risk of recall bias, Fatigue score compared
to baseline was not recorded at these late visits. Instead,
patients were asked to self-assess whether their symptoms had
relapsed, remained unchanged or had improved further since
the end of trial (18 months). The changes of SF-36-PF, percent
function level and mean steps, from baseline until extended
follow-up at 38–48 months, by response status, are shown in
Figures 5A–C.
At the 38–48 months visit, 36 out of 38 patients still
in the study completed the interview including assessment
of their percent function level, 35 recorded SF-36 forms
and 32 completed SenseWear activity measurements. Out of
22 responders, 20 completed the interview; 15 were still in
remission, while five reported a complete or partial relapse.
For 20 responders with available SF-36 recordings at 38–
48 months, the mean SF-36-PF was 70.8 (range 25–100)
compared to mean 69.5 at 18 months. SenseWear activity
registration was available for 19 out of 22 responders at
38–48 months with mean 6,415 steps per 24 h (SD 2,764),
compared to mean 5,589 (SD 2,017) at 18 months (Figure 5C).
Six patients with missing SenseWear data at 38–48 months
included two responders in ongoing remission, one in relapse and
three non-responders.
At baseline, only two of the responders had part-time work
participation. During follow-up, at least nine out of 22 responders
returned to either part-time of full-time work or studies.
HLA Data
Twelve of the 40 patients (30.0%) carried either of the two
specific HLA risk alleles. Ten of the 12 patients (83.3%)
positive for HLA alleles DQB1∗03:03 and/or C∗07:04 had a
response, compared to 12 out of 28 patients (42.9%) negative
for these HLA alleles (OR = 6.67; p = 0.028; Figure 6). The
allele HLA-C∗07:04 was present in four out of 40 patients
(10.0%), and three (75.0%) of these were responders. HLA-
DQB1∗03:03 was detected in 10 out of 40 patients (25.0%),
and 9 out of 10 (90.0%) were responders, compared to 13
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FIGURE 3 | SF-36 Physical Function (SF-36-PF) (A–D), percent function level (E–H), and mean steps per 24 h (I–L), means with 95% CI, at time points through 18
months follow-up. Outcome data for all included patients (n = 40) (A,E,I); Treatment-naïve (not previously exposed to rituximab, n = 25) (B,F,J); Responders during
follow-up (n = 22) (C,G,K); Non-responders during follow-up (n = 18) (D,H,L). P-values from General Linear Model repeated measures assessing changes in
outcome variable from baseline. P-values: * <0.05; ** <0.01; *** <0.001. SF-36 Physical Function with scale 0–100, higher number indicates better function. CI,
confidence intervals; SF-36, Short Form 36.
out of 30 HLA-DQB1∗03:03 negative patients (43.3%); OR =
11.8, p= 0.013.
Among 12 patients with the HLA alleles DQB1∗03:03
and/or C∗07:04, 7 (58.3%) had mild-to-moderate, 3 (25%)
had moderate, and 2 (16.7%) had moderate-to-severe
ME/CFS. Contrary, among 28 patients without these HLA
alleles, 7 (25.0%) had mild-to-moderate, 10 (35.7%) had
moderate, and 11 (39.3%) had moderate-to-severe ME/CFS
(p = 0.05). Eleven out of 12 patients (91.7%) with HLA
alleles DQB1∗03:03 and/or C∗07:04 were female, compared
to 20 out of 28 patients (71.4%) without these alleles
(p= 0.23).
Adverse Events
Adverse events (AE) for the complete period of 18 months
follow-up are shown in Table 2. Thirty-three patients (82.5%)
reported AEs of CTCAE grade ≥ 2, of which gastrointestinal
events such as nausea and constipation were the most
common. Out of 16 grade 3–4 events in 11 patients, 11
resulted in hospitalization and were reported as serious adverse
events (SAE, Supplementary Table 4). There was one suspected
unexpected serious adverse reaction (SUSAR), in a female
patient with moderate-to-severe ME/CFS who was a non-
responder in the study. She experienced gradual worsening
of postural orthostatic tachycardia syndrome (POTS) after
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FIGURE 4 | SF-36 Physical Function (SF-36-PF), means with 95% CI through 18 months follow-up, by subgroups. P-values from General Linear Model for interaction
time-by-group, assessing differences between the subgroups in repeated measures of SF-36-PF over time, compared to baseline. (A): By men vs. women; (B) By
ME/CFS severity; (C): By ME/CFS disease duration; (D) With or without self-reported infection prior to ME/CFS; (E) With or without previous rituximab treatment; (F):
With or without HLA risk alleles (HLA DQB1*03:03 and/or HLA C*07:04). SF-36, Short Form 36; CI, confidence intervals; HLA, Human Leukocyte Antigen.
cycle 4, resulting in hospital admission for 2 weeks. She had
experienced periods of similar POTS aggravations regularly
since she became ill with ME/CFS 18 years before study
inclusion. Her POTS symptoms gradually returned to baseline
level, but study treatment was discontinued. With routine
blood sampling before each cycle and after cycle 1 and 2,
there was no sign of hematological toxicity. Two women
both aged ≥41years at inclusion, experienced menopause after
start of treatment, two others reported irregular menstrual
bleeding that persisted to end of follow-up. One patient
without a clinical response suffered a sudden death of
unknown cause 4 years after inclusion in the study, i.e., 42
months after the last infusion, with no probable relation to
the intervention.
DISCUSSION
The present open-label phase II study with cyclophosphamide
infusions was well conducted with little missing data. More
than half of the patients had clinical response according to
the predefined criteria, many with long-lasting improvement of
symptoms. At extended follow-up 3–4 years after inclusion 68%
of responders were still in remission.
In general, the toxicity to cyclophosphamide infusions in
ME/CFS patients was moderate, and there were few serious
adverse events and no registered hematological toxicity. The
most common side effects were nausea and general malaise
lasting for 1–2 weeks after each infusion. ME/CFS patients
reported more nausea and discomfort after cyclophosphamide
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FIGURE 5 | Outcome variables at extended follow-up, by response status. Means with 95% CI at different time points including extended follow-up at 24–30 and at
38–48 months. (A): SF-36 Physical Function (SF-36-PF); (B) percent function level; (C): mean steps per 24 h. Numbers of patients at the different time points through
follow-up are shown below the graphs. SF-36, Short Form 36; CI, confidence intervals.
FIGURE 6 | Frequency of HLA risk alleles (HLA DQB1*03:03 and/or HLA
C*07:04) in responders and non-responders during follow-up. P-value from
Fischer’s exact test. HLA, Human Leukocyte Antigen.
than cancer patients typically do at similar doses, in line
with the generally low stress tolerance and sensitivity to drugs
reported by many patients. We reinforced the anti-emetic
regimen with aprepitant during the study in efforts to reduce
the nausea experienced by the patients during the first days
after infusion. Fertility concerns are an important toxicity issue
with chemotherapy. Cyclophosphamide is an alkylating agent
associated with ovarian failure and the risk increases with
higher cumulative doses and with increasing age (49, 50). One
study with intravenous infusions, applying similar cumulative
doses (mean 9.1 gram) as in the present study, and mean
age 31 years, reported ovarian failure in 13%, and transient
amenorrhea in 20% of the patients (51). In our present trial, two
women aged 41 and 46 years at inclusion experienced premature
menopause, and two others reported irregular menstruation
probably induced by the treatment at end of follow-up. In
contrast to spontaneous premature menopause, chemotherapy
associated ovarian dysfunction can resume over time (years) in
some patients, even after a prolonged period of amenorrhea and
elevated gonadotropin levels (52).
Since the 6-month initial treatment period with repeated
cyclophosphamide infusions in some patients led to increased
symptom burden and side effects, the extent and duration of
improvement in ME/CFS symptoms are important aspects to
justify the intervention. We therefore extended the follow-up
period, and collected additional clinical data from participants,
at 2–3 and 3–4 years after inclusion. The response durations were
sustained for most of the responders. Out of 22 responders 82%
were still in remission at 2–3 years and 68% at 3–4 years extended
follow-up. Seven even reported further improvement compared
to their status at 18 months follow-up. Also of note, three of the
patients who registered relapse at 3–4 years still reported a 2-fold
increase of their percent function levels as compared to baseline.
Thus, responders’ self-reported percent function levels, SF-36
Physical Function with increase from mean 35 at baseline to
mean >70 at 12 months, and measured levels of physical activity
(steps per 24 h), reflect clinically meaningful improvements of
their abilities and activities of daily life. For comparison, themean
SF-36 Physical Function in the general population is 84.2 (95%CI
71.9–96.5) (53).
Compared to the randomized RituxME trial assessing
rituximab vs. placebo in ME/CFS patients (35), the patterns
of improvement among patients in the present CycloME trial
seemed to be more homogeneous. In CycloME the clinical
responses occurred earlier than in the RituxME trial; at median
22 weeks compared to 41 weeks. In the CycloME study the
response rates were comparable between men and women, as
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TABLE 2 | Patients with adverse events of CTCAE grade 1–4 during 18 months
follow-up.
≥1 ≥2 3–4* Related to
study
treatment†
Patients with ≥ 1
adverse event
39 (97.5%) 33 (82.5%) 11 (27.5%) 29 (72.5%)
Nausea 36 (90%) 15 (37.5%) 0 36 (90%)
Constipation 22 (55%) 9 (22.5%) 1 (2.5%) 19 (47.5%)
Diarrhea 7 (17.5%) 1 (2.5%) 0 6 (15%)
Stomach pain 9 (22.5%) 2 (5%) 1 (2.5%) 7 (17.5%)
Infections 24 (60%) 15 (37.5%) 3 (7.5%) 13 (32.5%)
Irregular menstrual
bleeding
7 (17.5%) 3 (7.5%) 0 7 (17.5%)
Premature
menopause
2 (5%) 1 (2.5%) 0 2 (5%)
Haematuria 6 (15%) 1 (2.5%) 0 6 (15%)
Urinary bladder
symptoms**
5 (12.5%) 3 (7.5%) 0 5 (12.5%)
Hair loss 4 (10%) 0 0 4 (10%)
Rash or urticaria 6 (15%) 4 (10%) 1 (2.5%) 5 (12.5%)
Headache 12 (30%) 3 (7.5%) 1 (2.5%) 9 (22.5%)
Dizziness 6 (15%) 3 (7.5%) 0 5 (12.5%)
Edema of face or
limbs
6 (15%) 0 0 5 (12.5%)
Palpitations or
tachycardia
4 (10%) 2 (5%) 1 (2.5%) 2 (5%)
*11 grade 3–4 events for 8 patients were reported as SAE. See Supplementary Table 4
for details.
†Possible, probable or very likely relation to study treatment.
**Bladder/urinary tract pain or increased urinary frequency.
opposed to higher response in women in the RituxME trial.
The response rates were higher among patients with moderate
or moderate-to-severe disease, compared to the 4 patients with
severe ME/CFS who completed the intervention. In an ongoing
addition to the trial (part B), feasibility and response rate
are investigated in a small number of additional patients with
severe ME/CFS, to gain experience and to decide whether severe
patients may be included in a possible future randomized trial
assessing cyclophosphamide intervention.
The response rates were similar among patients who were
rituximab-naïve and patients who had participated in previous
trials with rituximab intervention (32, 33). Also, four out of
nine patients with no improvement after previous rituximab
intervention experienced clinical benefit after cyclophosphamide
in the present study.
Interestingly, the presence of either of the two HLA risk
alleles, previously shown to be associated with ME/CFS (HLA-
DQB1∗03:03 andHLA-C∗07:04) (30), was predictive for response
to cyclophosphamide. In contrast there was no association
between presence of these HLA alleles and clinical improvement
among patients included in the RituxME trial (35) (data
not shown).
The carrier frequency of any of these HLA risk alleles was
30% among ME/CFS patients in this trial, which is higher
than the 19.1% reported in the recent study of 426 Norwegian
ME/CFS patients (30). Western Norway is well represented in
this large cohort, and the frequency of DQB1∗03:03 and C∗07:04
from Western Norway sources did not differ from the national
frequency (data not shown). Therefore, geographical bias is not a
probable explanation.
The association between cyclophosphamide response and
the HLA risk alleles could be due to a true treatment effect
in individuals carrying these alleles. There are several reports
of associations between specific HLA alleles/haplotypes and
responses to immune modulatory treatments (54–57), but to
our knowledge this has not been demonstrated specifically
for cyclophosphamide. Another possibility is that carriers
of these HLA risk alleles constitute a subgroup among
ME/CFS patients with an immune-driven pathomechanism
generally responding better to immune modulating treatment.
Finally, the observed association between the HLA risk alleles
and response to cyclophosphamide could be coincidental,
but warrants further investigation in a possible future
randomized trial.
There are no biomarkers for ME/CFS or disease activity,
and assessments of symptom changes consequently have to
rely largely on self-recorded subjective variables. To increase
the validity of the measurements, we used several different
variables to measure symptom changes. These variables generally
showed the same patterns of improvement and worsening of
ME/CFS symptoms during the follow-up period. Self-reported
improvements in Fatigue score, percent function level and SF-
36 Physical Function scores correlated well, and with increased
levels of physical activity. “Steps per 24 hours” is an objective
measure, but not a perfect way to validate symptom improvement
because individual patients will use their improved energy for
different purposes. Some will walk, while some will prefer to read
or increase the time for social activity.
The initial patient observations in our cancer clinic, of
patients with long-standing ME/CFS who developed cancer,
and who reported relief of ME/CFS symptoms after cancer
treatment, included seven cases treated with cyclophosphamide
(or ifosfamide), and in one case the combination of
cyclophosphamide and rituximab. Our hypothesis was that
ME/CFS in a subgroup of patients could be caused by an
immunological dysfunction, possibly with a variant of an
autoimmune pathomechanism. In the present study, the
frequency of self-reported infection prior to ME/CFS debut
(65%) was in line with other reports (58). Also, there was a
high occurrence of autoimmunity among first-degree relatives
(55.0%). Both observations may support an immunological basis
for the disease. Initial phase II studies with rituximab (32, 33)
suggested that a subgroup of patients could benefit from B-cell
depletion therapy. Conversely, in the double-blind, placebo-
controlled, multicenter, phase III RituxME trial there were no
significant differences between the rituximab and placebo groups
for any of the primary or secondary outcome measures (35).
Taking the RituxME results into account, we have to interpret
the data from the present open-label CycloME trial with caution.
Patient selection, placebo mechanisms, patient’s expectations
in clinical trials, and natural variation of symptoms over time
may be operative (59, 60). Until a randomized trial has been
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performed, there is not sufficient evidence for a beneficial effect
of cyclophosphamide in ME/CFS patients.
Other study limitations are self-referral, use of self-reported
primary outcome measures with possible recall bias, and the
inclusion of patients who had participated in previous studies
with rituximab intervention. Although inclusion relied on strict
diagnostic criteria, the unknown etiology of ME/CFS and lack of
specific biomarkers could introduce unintended heterogeneity of
the patient sample.
When comparing the response data from the CycloME and
RituxME studies, it is important to consider the completely
different modes of action of the two drugs. Rituximab
is a monoclonal antibody which selectively depletes B-
cells expressing the CD20 protein on their surface, while
cyclophosphamide has broader immunosuppressive effects
on several subsets of lymphocytes. The main mechanism of
cyclophosphamide is the ability to covalently bind an alkyl
group, affecting mainly the DNA (61). This interaction is
irreversible and leads to inhibition of DNA replication and
apoptosis, producing cell death amongst resting and dividing
white blood cells and leading to impaired humoral and cellular
immune responses (62). Rapidly proliferating cells are most
sensitive to cyclophosphamide (41). This feature is utilized in
cancer therapy, but also to influence activated immune cells
that are present in different immune-mediated diseases (37).
The effects and side-effects of cyclophosphamide are highly
dose dependent. High doses can be used for the complete
eradication of hematopoietic cells, but lower doses are relatively
selective for T-cells, especially T-regulatory cells (T-regs).
Cyclophosphamide affects T-regs, which have a generally
higher proliferation rate than other T-cell subsets such as the
T-helper (Th) cells, but also affects B-cells and other cells
of the immune system (41). T-regs have an important role
in down-regulating the effects of Th cells, and help prevent
autoimmune diseases by maintaining self-tolerance (63). A
higher frequency of T-regs in ME/CFS patients compared to
healthy controls has been reported in some studies (64–66).
The T-reg markers are also general T-cell activation markers
(63). Thus, cyclophosphamide may interfere with the balance
between immune cell subsets and possibly counteract a
disease-facilitating environment.
Although the double blinded RituxME trial showed no
significant differences between the rituximab and placebo
groups for the outcome measures (35), there may still be
a subgroup of ME/CFS patients that have an autoantibody-
mediated disease where only few patients have autoantibody-
production from early CD20-positive plasmablasts that can be
targeted by rituximab. Other patients may still have autoantibody
production, but from long-lived CD20-negative plasma cells.
This mechanism is active in several rituximab refractory
autoimmune diseases and could be compatible both with the total
experience from our rituximab trials, and with the data from
the present cyclophosphamide trial. Cytotoxic chemotherapy,
such as cyclophosphamide, may inhibit B-cell activation and
proliferation to new antibody-secreting cells, thus reducing the
short-lived plasma cell compartment and recruitment of mature
plasma cells (67).
If an autoantibody-mediated mechanism is operative in a
subgroup of ME/CFS patients, the nature of possible endogenous
targets for pathogenic immunoglobulins is still elusive. Increased
serum levels of autoantibodies against several G-protein coupled
receptors have been shown in ME/CFS (16). Clinical symptoms
suggest inadequate regulation of autonomic functions and
blood flow, also demonstrated in a recent study of reduced
cerebral blood flow during head-up tilt test with orthostatic
stress using Doppler flow imaging of carotid and vertebral
arteries (68). Recent observations of patients with unexplained
exertional intolerance and dyspnea demonstrated a subgroup
with low ventricular filling pressure (preload failure) in upright
position during cardiopulmonary exercise tests, related to
reduced venous pressure (69, 70). Also, in patients with
unexplained exertional intolerance, a subgroup had impaired
systemic oxygen extraction, which may be associated with
microcirculatory dysregulation or mitochondrial dysfunction
(71). One might speculate on the possibility of an autoimmune
process indirectly of directly affecting blood vessels, or against
small nerve fibers including autonomic nerves regulating blood
vessel function. Small fiber neuropathy (SFN) is associated
with fatigue, postural orthostatic tachycardia syndrome (POTS),
gastrointestinal disturbances and abnormal sweating (72). SFN
has been demonstrated in 49% of fibromyalgia patients (73), and
in up to 43% of patients with preload failure, many of whom had
symptoms suggestive of ME/CFS (70). This could be associated
with inadequate autoregulation of blood flow according to the
demands of tissues, with local hypoxia and lactate accumulation
on limited exertion, and with metabolic adjustments which could
be secondary and compensatory in efforts to restore cellular
energy balance (20, 21, 23, 74, 75). Microvasculopathy may
also be reflected in arterial endothelial dysfunction which has
been demonstrated in ME/CFS (76), and also investigated in
substudies to the CycloME and RituxME trials (manuscripts
in preparation).
The growing evidence for immune disturbances in ME/CFS,
experience with cyclophosphamide in other autoimmune
diseases, with broad immunosuppressive effects on several
lymphocyte subsets including B-cells and T-regs, and the herein
reported association between HLA risk alleles and clinical
response to cyclophosphamide intervention, support that the
observed relief of ME/CFS symptoms could be a drug effect
targeting the underlying disease mechanisms. We strongly
advise patients and physicians not to use cyclophosphamide for
ME/CFS patients outside of clinical trials before a randomized
trial has been conducted, to evaluate the possible benefits of
the drug.
CONCLUSION
This study shows that cyclophosphamide intervention is
feasible for ME/CFS patients. The growing evidence for
immune alterations in ME/CFS and the high symptom
burden with very low quality of life, we believe can
justify use of an immune modulating drug with possible
side effects. The treatment period was demanding for
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most patients, but in total the toxicity was interpreted as
acceptable. The treatment was associated with long-lasting
improvements of ME/CFS symptoms for approximately half
of patients. However, due to the lack of a placebo group,
response data must be interpreted with great caution.
In the further work to find effective treatment, we will
consider a new multicenter, randomized, double-blind and
placebo-controlled trial with cyclophosphamide. Should this
trial prove cyclophosphamide to be beneficial for ME/CFS
patients, this could also be important in the search for relevant
disease mechanisms.
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